Investors' Corner
A Rare First-Mover Opportunity
TongueVǎge™ is positioned to create and own the powered tongue biofilm removal category — a whitespace no incumbent currently occupies.
Investor Disclosure
TongueVǎge™ seeks to create the powered tongue biofilm removal category. The business model of device plus recurring consumables is very similar to Waterpik, SmartMouth, Oral-B, and Philips Sonicare — making it a compelling acquisition target as well as a standalone growth opportunity.
Financial Projections
Scenario: 100,000 Active Users
Business Model
Revenue Streams Beyond the Device
Pari-mutuel wagering is the gateway — but it is not the ceiling. TongueVǎge™ is positioned to capture every layer of a diversified oral-care revenue architecture.
Device Sales
Premium device at $99–$120 retail ($55–$75 wholesale), targeting health-conscious consumers and clinical channels.
Replacement Cannulas
Recurring consumable — approximately 3 replacement tips per user annually at $14.99 retail ($8 net), generating $16 per user per year.
Tongue-Cleansing Solution
Proprietary rinse refill at $4/month net, generating $48 per user annually — a high-margin recurring revenue stream.
Professional Dental Version
Clinical-grade device for dental offices and hygienists — higher ASP, professional distribution through Dentsply Sirona and Henry Schein.
International Licensing
Licensing the TongueVǎge™ technology and brand to international oral-care distributors in markets where direct operations are not yet established.
Exit Strategy
Estimated Enterprise Value
Consumer-health companies commonly sell for approximately 3–5× revenue or 8–12× EBITDA. At $11.9M annual revenue and 25–30% EBITDA margins, TongueVǎge™ presents a compelling acquisition profile.
Low
$35 Million
3–5× Revenue
Mid
$50 Million
8–10× EBITDA
High
$70 Million
10–12× EBITDA
Target acquirers include Waterpik, SmartMouth, Oral-B, and Philips Sonicare — companies that already understand irrigation-based oral care and would immediately grasp the value proposition.
Accredited Investors Only
Definition
An accredited investor is an individual or entity that the U.S. Securities and Exchange Commission (SEC) deems financially sophisticated enough to participate in private investment offerings that are exempt from standard registration requirements — based on income, net worth, or professional credentials.
An accredited investor is an individual or organization that meets financial or professional qualifications established by the U.S. Securities and Exchange Commission (SEC). Many private investment opportunities are available only to accredited investors under federal securities laws.
Net Worth
More than $1 million, individually or jointly with a spouse or spousal equivalent, excluding the value of the primary residence.
Income
Annual income exceeding $200,000 individually, or $300,000 jointly with a spouse or spousal equivalent, in each of the two most recent years, with a reasonable expectation of reaching the same level in the current year.
Professional Credentials
Holding certain SEC-recognized securities licenses, including the Series 7, Series 65, or Series 82.
Important Notice
Accredited-investor status does not mean an investment is risk-free or endorsed by the SEC. Investors should carefully evaluate all investment opportunities and consult their own legal, tax, and financial advisors before making any investment decision. This information is provided for educational purposes only and does not constitute an offer to sell, or a solicitation to purchase, any security.
Projections presented herein are best-guess estimates based on the current healthcare market and industry outlook, current products and devices for oral hygiene. There is no expressed or implied guarantee of success; and, there is a risk of financial loss. Therefore, this offer is only available to accredited investors.